T he development of gene transfer for the treatment of thalassemia has been a goal for more than three decades (Mercola and Cline 1980) . The anticipated targets for gene transfer are hematopoietic stem cells (Naldini 2011; Rivière et al. 2012) . Stem and progenitor cells are to be harvested from patient bone marrow or peripheral blood following cytokine mobilization, purified by immunoselection, transduced, and returned to the patient (Fig. 1 ). Various types of vectors have been considered for gene transfer into stem cells, with integrating retroviruses being the leading candidate. Recently, one participant in an ongoing gene transfer trial for severe b-thalassemia has achieved clinical benefit with elimination of his transfusion requirement (Cavazzana-Calvo et al. 2010) .
Overall, the field of gene therapy evolved slowly over the last three decades (Weatherall 1988) . In 1995, the NIH Director convened a panel of experts to evaluate the field (Orkin and Motulsky 1995) . Numerous, early clinical trials had been unsuccessful and uninformative. The panel, while noting that well-designed clinical trials are necessary to advance a new therapy, concluded that the methodology of gene transfer had not yet evolved to justify widespread attempts at clinical trials. Proof of efficacy in relevant preclinical models was judged to be necessary before attempting additional clinical trials. Although some academic investigators remained committed to preclinical research and ultimately to clinical trials, commercial interest declined, and there was a general sense of pessimism that pervaded the field. severe combined immunodeficiency (SCID) secondary to deficiency in the common g-chain (X-SCID) (Hacein-Bey-Abina et al. 2002 , 2010 Gaspar et al. 2004 Gaspar et al. , 2011b or adenosine deaminase deficiency (ADA-SCID) (Aiuti et al. 2002 (Aiuti et al. , 2009 Gaspar et al. 2011b ). Gene-corrected lymphoid cells in these disorders have a growth advantage compared with uncorrected cells and fully repopulate the lymphoid tissues. Gammaretroviral vectors, based on a mouse tumor virus, were used with the coding sequences for the missing protein encoded by a cDNA under the control of the enhancer/promoter elements in the long terminal repeats (LTRs). This initial experience with successful gene therapy has recently been reviewed (Naldini 2011; Rivière et al. 2012) . Twenty patients with X-SCID and 40 patients with ADA deficiency have undergone the gene transfer procedure. Generally, the procedure has been successful with recovery of lymphoid elements and correction of the immuno-deficiency, although the procedure has failed in a few older patients with ADA deficiency (Thrasher et al. 2005; Gaspar et al. 2011a) . A similar vector was used to treat three individuals with chronic granulomatous disease (CGD) (Ott et al. 2006) . Although clinical improvement occurred in two patients initially, complications-to be described below-limited the overall outcome. Recently, a successful gene therapy trial has also been reported for Wiskott -Aldrich syndrome (WAS), with 10 participants showing evidence of clinical improvement (Boztug et al. 2010; Braun et al. 2011; C Klein, pers. comm.) . These trials provided proof-of-principle that stem cell-targeted gene transfer can achieve a therapeutic benefit.
The gene therapy trials that used a gammaretroviral vector with intact LTRs have been complicated by insertional mutagenesis and proto-oncogene activation (Hacein-Bey-Abina et al. 2003 Howe et al. 2008) . Five of the Cavazzano-Calvo et al. 2010) . After purification, the hematopoietic stem cells (HSCs) were maintained in culture for 34 h. Lentiviral vector particles containing a functional b-globin gene were added, and culture was continued for 18 h. The patient underwent chemotherapy to eradicate the remaining HSCs and make room for the genetically modified cells. The transduced HSCs were then transplanted into the patient by infusion into a peripheral vein. (Adapted from Persons 2010; reprinted, with permission, from the author.) 20 participants in the trials for X-SCID have developed T-cell leukemia. Recently, four of the 10 participants in the trial for WAS have also developed leukemia (Braun et al. 2011; C Klein, pers. comm.) . Three patients with CGD developed myelodysplastic syndrome, and one has died of acute myeloid leukemia (Stein et al. 2010) . Although the risk of insertional mutagenesis with proto-oncogene activation was recognized when the trials were initiated, this complication was not observed in murine models or in large animal studies over the years (Kiem et al. 2004; Nienhuis et al. 2006) . Only one monkey developed myeloid leukemia 5 yr after the gene transfer procedure, thought secondary to vector-mediated inactivation of an anti-apoptotic gene (Seggewiss et al. 2006) .
Studies of the pattern of vector integration in patients from the gene therapy trials has uncovered a skewed pattern with preferential integration near or within transcriptionally active genes (Cattoglio et al. 2007; Deichmann et al. 2007 Deichmann et al. , 2011 Schwarzwaelder et al. 2007; Biasco et al. 2012) . Remarkably, the majority of patients with leukemia in both the X-SCID and WAS trials had an insertion near or within the LM02 gene, suggesting that its activation was the initiating event in the development of leukemia (Hacein-Bey-Abina et al. 2003 Schwarzwaelder et al. 2007; Braun et al. 2011; C Klein, pers. comm.) . Integrations in the CGD patients were found in the MDS-EVI1, PRDM1, and SETB1 loci (Stein et al. 2010) . None of the patients with ADA deficiency has developed leukemia despite vector integration near or within proto-oncogenes including the LM02 gene (Aiuti et al. 2007 ). The basis for the different outcomes for X-SCID versus ADA-SCID is not understood. A recent review discusses the various possibilities (Shaw and Kohn 2011) .
POTENTIALLY SAFER INTEGRATING RETROVIRAL VECTORS
The occurrence of leukemia in the trials for X-SCID, WAS, and CGD has prompted a search for safer vectors, as recently reviewed comprehensively (Wu and Dunbar 2011; Cooray et al. 2012) . A self-inactivating (SIN) design involves removal of the enhancer/promoter from the 3 0 LTR. During retroviral integration, a portion of the 5 0 LTR is copied from the 3 0 LTR so that both LTRs lack the enhancer/promoter in the integrated SIN vector genome, thereby reducing the risk for proto-oncogene activation (Yu et al. 1986; Zufferey et al. 1998 ). The SIN design requires the use of an internal promoter, either retroviral or cellular, to achieve expression of the therapeutic transgene. A SIN design has been applied to deriving a gammaretroviral vector that is now in clinical trials for X-SCID in the United States and Europe (Thornhill et al. 2008) . Success in the first patient treated with the new vector (Pai et al. 2011 ) was reported at the most recent meeting of the American Society of Hematology.
Another modification designed to improve safety is the incorporation of an insulator element into the vector. The insulator element is usually placed in the 3 0 LTR of a SIN vector so that it is copied over into the 5 0 LTR upon vector integration, resulting in flanking of the transgene with insulator elements (Emery 2011; Cooray et al. 2012) . The most well studied of insulator elements is that located in the 5 0 hypersensitive site 4 (HS4) of the chicken b-globin gene locus ( Fig. 2) (Chung et al. 1993 (Chung et al. , 1997 Giles et al. 2010) . This insulator has two separable activities; it protects integrated transgenes from silencing by nearby heterochromatin, a socalled barrier activity, and it also blocks interaction between linked enhancer and promoter elements when located between the two (Recillas-Targa et al. 2002) . As a barrier element, the insulator prevents spread of silencing histone modifications into the transcribed locus and CpG methylation of the protected promoter sequences (Pikaart et al. 1998) . Experimentally, the erythroid-specific LCR elements included in globin gene lentiviral vectors did not activate the proto-oncogene LM02 in human T-cells as expected (Ryu et al. 2008) , and the cHS4 insulator reduced gene activation by LCR elements in human erythroleukemia cells (Ryu et al. 2007 ).
The activities of HS4 have been mapped to a 275-bp core element, which includes five protein-binding sites as determined by DNase I footprinting ( Fig. 2) (Chung et al. 1997; Giles et al. 2010 ). The sites have been designated footprint I through footprint V (FI, FII, FIII, FIV, and FV). FII binds the protein CTCF, and this protein is sufficient for enhancer blocking through its interaction with other proteins and intracellular membranes (Bell et al. 1999; Giles et al. 2010; Ghirlando et al. 2012 ). CTCF and associated proteins anchor the insulator to nuclear structures including the nucleolus, creating a chromatin loop that is thought to inhibit enhancer-promoter interactions. FIV is required for barrier activity and has been shown to bind USF proteins that recruit histone-modifying enzymes associated with transcriptionally active chromatin (West et al. 2004) . Such recruitment appears to block encroachment of transcriptionally repressive chromatin into the transcribed region. The remaining protein-binding sites (F1, FIII, and FV) have all been shown to bind the protein VEZF1, which, in the context of recruiting other proteins, protects downstream DNA within the transcribed region from DNA methylation, particularly of promoter elements (Dickson et al. 2010 ). Overall, insulators are involved in the organization of chromatin domains and in maintaining boundaries, specifically those between repressed chromatin and transcriptionally active chromatin structure (Ghirlando et al. 2012; Kolovos et al. 2012 ). Other insulators have been considered for vector development, and a limited number have been tested (Emery 2011) . For example, a combination of FII from the chicken HS4 and a homologous region from the T-cell receptor, a/ d BEAD-1 insulator greatly reduced the transforming potential of retroviral vectors (Ramezani et al. 2008) .
DEVELOPMENT OF GLOBIN GENE VECTORS Gammaretroviral Vectors
Early studies explored the use of DNA viruses including SV40 (Mulligan et al. 1979 ), adenovirus (Karlsson et al. 1986) , and adeno-associated viral vectors (Walsh et al. 1992; Maina et al. 2008 ) for transfer of globin-encoding sequences. However, integrating gammaretroviral vectors was judged to be potentially more suitable for achieving permanent genetic modification of hematopoietic cells. With evolving knowledge of the b-globin gene locus, retroviral vectors were constructed that incorporated the natural promoter sequences, the introns, and the 3 0 -untranslated sequences in an effort to enhance expression (Cone et al. 1987 ). Transfer of the complete globin gene into murine stem cells could be accomplished, but the level of expression remained relatively low (Cone et al. 1987; Karlsson et al. 1987; Dzierzak et al. 1988; Sadelain et al. 1995) .
Locus Control Region
Only with the discovery of the locus control region (LCR) upstream from the b-globin gene cluster did it become feasible to design vectors that achieved higher levels of expression. (Arrows) DNase I hypersensitive sites. The core of the HS4 element is expanded to show the positions of the five in vitro footprinted sequences (Chung et al. 1997) .
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The LCR was discovered by virtue of its functional activity in providing copy number-dependent, integration site-independent globin gene expression in erythroid cells in transgenic mice (Grosveld et al. 1987) . Four DNase I hypersensitive (HS) sites are distributed over 20 kb upstream from the human b-globin gene locus (Tuan and London 1984; Tuan et al. 1985; Forrester et al. 1987) . Each HS site marks a 200-to 400-bp core element of exposed DNA that includes binding sites for many erythroid or ubiquitously expressed transcriptional factors. The LCR is thought to function by forming a folded structure whereby multiple proteins bound to HS sites interact in forming a holocomplex, which by virtue of loop formation is brought into contact with a promoter within a transcription factory within the nucleus, thereby activating that promoter (Palstra et al. 2008; Schoenfelder et al. 2010; Edelman and Fraser 2012) .
Gammaretroviral Vectors Continued
The series of HS sites upstream from the 1-globin gene has been tailored to minimize the size of vectors by focusing on the core, HS elements for use in gene transfer vectors (Plavec et al. 1993; Emery et al. 1998 ). Unfortunately, these elements often resulted in gammaretroviral vector instability with low titer. Various strategies were attempted to overcome these limitations, but none was fully successful (Novak et al. 1990; Chang et al. 1992; Takekoshi et al. 1995; Ren et al. 1996; Sabatino et al. 2000; Fragkos et al. 2005) . Extensive mutagenesis was required to achieve adequate titers with vectors containing multiple HS sites from the b-globin locus to remove potential splice or polyadenylation sites and to eliminate sequences in the b-globin gene that were unnecessary and reduced titer (Leboulch et al. 1994) . Another approach that gave results that were somewhat encouraging was the screening of many vectors to identify one that gave a fairly high titer despite the presence of multiple HS fragments. However, highly variable expression was found in mouse erythroleukemia cell clones containing the vector that had been selected based on titer (Sadelain et al. 1995) . Addition of an insulator improved expression (Emery et al. 2000) as did other modifications designed to increase globin gene expression (Li et al. 1999) . Efforts continued through 2002 to adapt gammaretroviral vectors for transfer of a globin gene with high expression (Nicolini et al. 2002; Emory et al. 2002) . Such vectors were also tested for their ability either to correct b-thalassemia in a mouse model (Nishino et al. 2006) or to express an antisickling b-globin in human cells from patients with sickle cell disease (Oh et al. 2004 ). Overall, the extensive efforts over nearly two decades to develop gammaretroviral vectors for globin gene transfer had limited success (Ellis and Pannell 2001) , and ultimately committed investigators migrated to the use of lentiviral vectors because of the advantages discussed in the next section.
Lentiviral Vectors
Lentiviral vectors based on the genome of human immunodeficiency virus (HIV) have several inherent advantages for stem cell -targeted gene transfer (Naldini et al. 1996) . HIV-based vectors are able to transduce non-mitotic cells because of the ability of the preintegration complex (PIC) to traverse the intact nuclear membrane, a property that is dependent on the inclusion of specific viral sequences within the gene transfer vector (Follenzi et al. 2000; Sirven et al. 2000; Zennou et al. 2000; Cooray et al. 2012 ). In addition, the PIC of HIV-based vectors persists in the nucleus much longer than the PIC of gammaretroviral vectors, thereby extending the window during which vector integration may occur (Hass et al. 2000) . Activation of the quiescent hematopoietic cells to the G 0 / G 1 phase of the cell cycle is required for lentiviral vector transduction (Uchida et al. 1998; Case et al. 1999; Sutton et al. 1999) . Lentiviral vectors can be packaged with a variety of envelope proteins (Naldini and Verma 2000) . Historically, the envelope protein from vesicular stomatitis virus (VSV-G) has been used to pseudotype lentiviral vector particles for experimental use.
A recent study confirms that particles having the VSV-G envelope protein are superior at transducing CD34 þ cells relative to the envelope proteins of several gammaretroviruses (Kim et al. 2010 ). The chicken HS4 insulator has also been tested within the LTRs of a SIN lentiviral globin vector. Its incorporation into the vector may reduce titer , but optimization has been found to improve titer and transgene expression (Arumugam et al. 2007; Hanawa et al. 2009 ). The core 250-bp element of the cHS4 insulator has been extended with sequences immediately downstream or with sequences from the 3 0 end of the cHS4 fragment ) in efforts to improve vector expression. Overall results suggest that the use of chromatin insulators may improve the expression and safety of integrating gene transfer vectors as summarized in a recent review (Emery 2011) .
Although gammaretroviral vectors have a predilection to integrate near transcriptional start sites (Wu et al. 2003) , HIV-based lentiviral vector genomes are more uniformly distributed throughout transcribed genes (Schröder et al. 2002) . Preferential intragenic integration has also been shown for a b-globin gene vector in human and murine hematopoietic cells (Imren et al. 2004; Ronen et al. 2011) . This is only a relative advantage because inactivation of a tumor suppressor gene may occur with intragenic integration. In addition, some lentiviral vector integrations do indeed occur near a transcription start site. Nonetheless, direct comparison in a tumor-prone mouse model suggests that SIN lentiviral vectors with an internal promoter are significantly less genotoxic than standard gammaretroviral vectors with intact LTRs (Montini et al. 2006) . Aberrant splicing events are much reduced by use of SIN lentiviral vector design compared with vectors having intact LTRs (Cesana et al. 2012) . Recent data also suggest that the lentiviral vector integration profile in preclinical models and in a clinical trial is inherently less oncogenic than that of gammaretroviral vectors (Biffi et al. 2011 ). However, insertional mutagenesis and gene activation have been documented with lentiviral vectors (Hargrove et al. 2008; Modlich et al. 2009; Montini et al. 2009 ), which has led to the development of leukemia in a murine model (Heckl et al. 2012) . Thus, use of lentiviral vectors will likely mitigate, but not eliminate, the risk of insertional mutagenesis.
HIV-based vectors having a SIN design are in clinical trials for metachromatic leukodystrophy (MLD) (Biffi and Naldini 2007) , adrenoleukodystrophy (ALD) (Cartier et al. 2009 (Cartier et al. , 2012 , WAS (Galy and Thrasher 2011; Scaramuzza et al. 2012) , and indeed for b-thalassemia (Cavazzana-Calvo et al. 2010). The results in four patients with MLD are particularly striking in that expression of the therapeutic transgene occurred in .50% of hematopoietic cells following stem cell transduction and autologous transplantation with major clinical benefit (A Biffi and L Naldini, pers. comm.). Thus, the greater efficiency of gene transfer into stem cells that had been predicted for lentiviral vectors has apparently been achieved in these early clinical trials.
Another advantage of lentiviral vectors is their well-developed mechanism for nuclearto-cytoplasmic transfer of unspliced mRNA, which facilitated the inclusion of globin genes with intact introns, LCR fragments, and insulator elements (May et al. 2000; Pawliuk et al. 2001) . Globin vectors were envisioned as potentially being therapeutically useful both for thalassemia and sickle cell disease. Accordingly, an anti-sickling variant (Oh et al. 2004) or the natural g-globin gene ) has been used to facilitate their ultimate use in treatment of sickle cell disease.
Correction of Mouse Models
Transgenic mouse strains having either severe b-thalassemia (Ciavatta et al. 1995; Yang et al. 1995) or sickle cell disease (Pászty et al. 1997) have been derived by the standard transgenic and/or homologous recombination methodologies. Globin vectors have been tested for their ability to correct these phenotypes. Quantitative studies using various transgenic mouse strains had suggested that expression of a transgene in 20% of the erythroid precursors along with achievement of expression at 20% of the level of the normal b-globin gene was likely to be sufficient to correct the phenotype of b-thalassemia intermedia in the mouse model (Persons et al. 2001) . Similar studies were performed in the sickle mouse model and suggested that 9% -16% HbF significantly improved the sickle phenotype (Blouin et al. 2000) . Collectively, these studies supported the therapeutic potential of available globin gene vectors for correcting hemoglobin disorders.
Several studies have shown that lentiviral vector-mediated globin gene transfer will ameliorate the phenotype of murine thalassemia intermedia May et al. 2002; Persons et al. 2003a; Hanawa et al. 2004; Negre et al. 2011 ). A mouse model of thalassemia major was developed by transplanting adult mice, following lethal irradiation, with fetal liver cells taken from homozygous, b-globin-null mice. These animals developed severe anemia and massive splenomegaly as well as extramedullary hematopoiesis by 60 d of age (Rivella et al. 2003) . The phenotype could be rescued by lentiviral vector-mediated, globin gene transfer into the fetal liver cells before transplantation. Significant correction of the erythroid phenotype occurred in animals in which .95% of the hemoglobin contained a human b-globin chain (Rivella et al. 2003) . Several studies have also documented the ability of lentiviral vectors to ameliorate or correct the phenotype of sickle cell disease in the mouse model (Pawliuk et al. 2001; Levasseru et al. 2003; Perumbeti et al. 2009; Pestina et al. 2009 ).
Correction of Human Thalassemic Erythroid Cells
Lentiviral vectors will also correct the phenotype of b-thalassemia major in cultured erythroid cells derived from patients with this disorder. Production of normal amounts of bglobin has been achieved in erythroid cultures with correction of ineffective erythropoiesis and a reduction in apoptosis (Puthenveetil et al. 2004 ). Gene-corrected primitive cells were transplanted into immune-deficient mice, and effective human erythropoiesis was documented 3-4 mo after transplantation (Puthenveetil et al. 2004) . A recent study that used cells from a large number of patients provided additional evidence that the b-thalassemia major pheno-type may be corrected by gene transfer (Roselli et al. 2010) . Therapeutic levels of fetal hemoglobin have also been achieved in erythroid progeny of b-thalassemic CD34 þ cells after lentiviral vector-mediated g-globin gene transfer in a twostage culture system (Fig. 3) (Wilberet al. 2011a ).
In Vivo Selection
Of concern with regard to the development of future clinical trials for treatment of severe bthalassemia is the level of stem cell transduction that can be achieved. Strategies have been explored to amplify the genetically modified stem cell pool in vivo to increase its contribution to hematopoiesis relative to the contribution of non-transduced stem cells. A dual gene vector encoding g-globin with associated LCR elements and a variant methylguanine methyltransferase, driven by a constitutive promoter, has been used to transduce repopulating cells in the mouse model. On initial reconstitution, animals had subtherapeutic levels of g-globinexpressing cells, but in vivo drug selection amplified the genetically modified population, leading to correction of the b-thalassemia intermedia phenotype in the murine model (Persons et al. 2003b; Zhao et al. 2009 ). Selective amplification of genetically modified cells by drug selection has also been achieved in nonhuman primate models (Larochelle et al. 2009; Beard et al. 2010) .
CLINICAL TRIALS FOR SEVERE b-THALASSEMIA
Plans for the first clinical trial using a lentiviral vector to transfer a globin gene into bone marrow cells from patients with b-thalassemia were announced in 2005 (Bank et al. 2005) . The lentiviral vector that was used is a self-inactivating variant that included large segments of the blocus control region as well as 250-bp core elements from the chicken HS4 insulator in the LTRs (Fig. 4) . To date, three participants have been enrolled on the clinical trial, which is open in Paris (Cavazzana-Calvo et al. 2010; P Leboulch, pers. comm.) . The vector encodes a mutated adult b-globin [b A (T87Q)] that has anti-sickling properties and can be distinguished from normal adult b-globin by high performance liquid chromatography. The first patient failed to engraft because the purified CD34 þ cells had been compromised technically without relation to the gene therapy vector. The second participant has now been followed for 5 yr after the gene transfer procedure. His clin-ical course is described in detail below. The third patient was transplanted 2 mo ago without complication. Hematopoietic reconstitution is ongoing, and the variant b-globin can be detected in blood reticulocytes.
The second participant in the clinical trial was 18 yr old at the time of treatment and has now been followed for nearly 5 yr following the Figure 3 . Two-stage culture model of human erythropoiesis. CD34 þ cells from normal or thalassemic individuals are initiated into culture in medium designed to expand erythroid progenitors. The CD34 þ cells are transduced with a retroviral vector between days 2 and 4 of the expansion phase of the culture. After 8 d, the culture medium is changed to one that favors erythroid differentiation. Full hemoglobinization and often enucleation of the red cells can be achieved, indicating significant maturation. Aliquots were taken at various intervals and at the end of culture to analyze the pattern of hemoglobin production. gene transfer procedure (Cavazzana-Calvo et al. 2010) . He has severe b E /b 0 -thalassemia and began on regular transfusion therapy at age 3 because of severe and poorly tolerated anemia and significant enlargement of the liver and spleen. Splenectomy was performed at age 6. The participant was conditioned with intravenous Busulfex (3.2 mg/kg per day). His transduced bone marrow CD34 þ cells were found to have 0.6 vector genomes/transduced cell. The patient received the transduced bone marrow cells in early June of 2007 and was last transfused in early June of 2008. His Hb level has remained between 9 and 10 g/dL. Approximately onethird of the total hemoglobin is composed of the therapeutic hemoglobin Hb-b A (T87Q), one-third of which is HbE and one-third is HbF. The ratio of g to b E globin did not change following the transplant procedure, suggesting that enhancement of HbF production was not a significant factor in the patient's clinical improvement. The patient has undergone frequent phlebotomies to accelerate the clearance of iron that had accumulated during the several years that he was transfusion dependent.
Insertion site analysis detected a dominant clone in which the vector was integrated into the high-mobility group AT-Hook2 (HMGA2) locus in granulocytes, monocytes, and erythroblasts (Cavazzana-Calvo et al. 2010 ). This integration site was not found in lymphoid cells. The proportion of genetically modified cells in whole blood increased gradually over time, but the clone having the HMGA2 integration site remained stable at 2% total blood cells. Molecular analysis indicated that the HMGA2 gene that had been disrupted by vector integration was actively expressed. All three exons were contained within a truncated RNA product that arose by alternate splicing of the third exon into a cryptic 3 0 splice signal located within the insulator core and cleavage/polyadenylation within the adjacent LTR. The disrupted locus encodes a chimeric protein in that the first 83 amino acids are encoded by the three HMGA2 exons fused to 52 amino acids from the readthrough transcript. Missing from this chimeric RNA is the normal 3 0 untranslated region, which includes two binding sites for LET7 microRNA, which is thought to decrease stability of the transcript within the cytoplasm. Analysis of erythroid cells suggested that the HMGA2 integration site was not particularly favorable for high expression of the transferred globin gene.
A multicenter phase I clinical trial to evaluate globin gene transfer in b-thalassemia is being developed and led by Michel Sadelain of Memorial Sloan-Kettering Cancer Center (Sadelain et al. 2010) . A collaboration between investigators in Greece and in Seattle has also been established to begin preparation for a clinical trial. These investigators have compared mobilization of stem cells with G-CSF alone, mobilization with G-CSF after 1 mo of pretreatment with hydroxyurea to prevent hyperleukocytosis and splenic enlargement, and mobilization with plerixafor. Plerixafor resulted in rapid and effective mobilization in both splenectomized and unsplectomized patients and was well tolerated (Yannaki et al. 2012) . We are also planning a trial at St. Jude Children's Research Hospital.
In summary, gene therapy trials for b-thalassemia are underway or soon to begin. One patient clearly benefited from the gene transfer procedure but in the context of clonal dominance secondary to proto-oncogene activation. This outcome is reminiscent of experience with gammaretroviral gene transfer for the treatment of CGD (Grez et al. 2011) . In general, although a clinical benefit has been achieved in several CGD patients, the presence of genetically modified cells has been transient and nearly undetectable in most after a few months following the transplant procedure. Of the 12 patients with CGD who have been treated by gene therapy, only three engrafted with high levels of genemodified cells long term, and in all three cases, clonal expansion was triggered by insertional activation of the proto-oncogene EVI1 (Grez et al. 2011 ). On the other hand, the outcomes with lentiviral vectors for metachromatic leukodystrophy (A Biffi and L Naldini, pers. comm.) and adrenoleukodystrophy (Cartier et al. 2009 (Cartier et al. , 2012 have generally been more favorable, with persistence of high levels of genetically modified cells for months to years following gene transfer. Only further clinical experience will determine which outcome is most likely for most patients with b-thalassemia. Table 1 are the transduction conditions and outcomes in the lentiviral clinical trials conducted to date. Incorporated into the conditions used for transduction for the metachromatic leukodystrophy trial are strategies to reduce proteasome activity (Santoni de Sio et al. 2008 . Prior studies had shown that lentiviral vector-mediated gene transfer into mobilized peripheral blood stem cells is restricted by proteasome activity and that such activity is down-regulated by early active cytokines that enhance transduction. A period of 12 h rest was incorporated into the transduction protocol to allow cells to recover with reduced proteasome activity, and a proteasome inhibitor was included in the culture medium.
STRATEGIES TO IMPROVE STEM CELL -TARGETED GENE TRANSFER

Compared in
Various other strategies have also been proposed to increase the proliferative potential of primitive cells and to enhance their engraftment. These include transient silencing of PTEN ( phosphatase tensin homolog deleted on chromosome 10) (Kim et al. 2012 ); inhibition of aldehyde dehydrogenase, which increased radioprotective capacity in the murine model (Muramoto et al. 2010) ; and addition of nicotinamide, an inhibitor of various ribosylases, which enhances hematopoietic stem cell activity in the context of ex vivo expansion of functional CD34 þ cells (Peled et al. 2012) . Whether any of these strategies will ultimately be applicable to the in vitro transduction of hematopoietic stem cells with therapeutic vectors remains to be determined. Efforts are also focused on understanding homing and engraftment with the ultimate goal of improving the outcome of the gene transfer procedure . Rather than transferring a globin gene, another approach would involve the activation of the endogenous g-globin genes to compensate for the lack of b-globin synthesis (Wilber et al. 2011b) . Future prospects include the development of targeted vectors with improved efficiency of gene transfer into stem cells (Verhoeyen et al. 2012) . Ongoing efforts are also directed toward achieving targeted correction of the causative mutation in repopulating stem cells by homologous recombination (Lombardo et al. 2011) . Recently, alternative targets for gene transfer including induced pluripotent stem cells derived from patients' somatic cells have been proposed, although the development of this strategy is far more distant than stem cell-targeted gene transfer (Papapetrou et al. 2011).
CONCLUDING REMARKS
Three decades of effort to achieve therapeutic globin gene transfer has ultimately proved productive despite periods in which success seemed quite distant. Basic discoveries such as the development of lentiviral vectors and the characterization of the b-globin LCR were essential milestones on the road to potential success. One patient with a severe form of b-thalassemia has clearly benefitted, with achievement of transfusion independence albeit with clonal dominance. Ongoing trials for metachromatic leukodystrophy and adrenoleukodystrophy suggest that therapeutic levels of gene transfer into repopulating stem cells can be achieved. Further refinements in the methodology for gene transfer is likely to bring more definite success for the treatment of b-thalassemia.
